Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Torrent Pharmaceuticals Limited |
---|---|
Information provided by: | Torrent Pharmaceuticals Limited |
ClinicalTrials.gov Identifier: | NCT00932880 |
Objective:
Study Design:
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Amlodipine Besylate Drug: Norvasc |
Phase I |
Study Type: | Interventional |
Official Title: | An Open-Label, Randomized, Two-Way Crossover, Single Dose Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets [Torrent Pharmaceuticals Limited,India] Compared to a 10 mg Dose of Norvasc®, [Pfizer, USA] in 18 Fed, Healthy Adult Subjects |
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 20-061-SA |
Study First Received: | July 1, 2009 |
Last Updated: | July 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00932880 History of Changes |
Health Authority: | United States: Institutional Review Board |
Calcium, Dietary Vasodilator Agents Calcium Channel Blockers Cardiovascular Agents |
Healthy Antihypertensive Agents Amlodipine |
Membrane Transport Modulators Vasodilator Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Calcium Channel Blockers |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Amlodipine |